Literature DB >> 16185764

Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing.

T Nagasawa1, Q Zhang, P N Raghunath, H Y Wong, M El-Salem, A Szallasi, M Marzec, P Gimotty, A H Rook, E C Vonderheid, N Odum, M A Wasik.   

Abstract

To understand better T-cell lymphomagenesis, we examined promoter CpG methylation and mRNA expression of closely related genes encoding p16, p15, and p14 tumor suppressor genes in cultured malignant T-cells that were derived from cutaneous, adult type, and anaplastic lymphoma kinase (ALK)-expressing T-cell lymphomas. p16 gene was epigenetically silenced in all but one of the 10 malignant T-cell lines examined, p15 gene silenced in roughly half of the lines, and p14 was the least frequently affected. Extensive methylation of the p16 promoter was seen in six out of 10 cutaneous T-cell lymphoma patient samples and corresponded with lack of p16 protein expression in the cases examined. Treatment of cultured T-cells with the DNA methyltransferase inhibitor, 5-aza-2-deoxy-cytidine, resulted in reversal of the p16 gene silencing. However, expression of p16 protein was delayed in relationship to p16 promoter demethylation and required up to 3 weeks to occur, seemingly reflecting late activation of the p16 gene. These findings indicate that epigenetic silencing affects in T-cell malignancies, often simultaneously, several tumor suppressor genes that impact on key cell functions. The observed differential silencing of p16 and p14, and to a lesser degree p15 gene, indicates that the silencing is governed by precise, promoter region-specific mechanisms. The study provides also further rationale for treatment of at least some types of T-cell lymphomas with DNA methyltransferase inhibitors to target the epigenetically silenced tumor suppressor genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185764     DOI: 10.1016/j.leukres.2005.08.012

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

Review 1.  Mycosis fungoides and sezary syndrome: an update.

Authors:  Ellen J Kim; Julie Lin; Jacqueline M Junkins-Hopkins; Carmela C Vittorio; Alain H Rook
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

2.  STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes.

Authors:  Qian Zhang; Hong Y Wang; Anders Woetmann; Puthiyaveettil N Raghunath; Niels Odum; Mariusz A Wasik
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

3.  Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.

Authors:  Elif Karaca Atabay; Carmen Mecca; Qi Wang; Chiara Ambrogio; Ines Mota; Nina Prokoph; Giulia Mura; Cinzia Martinengo; Enrico Patrucco; Giulia Leonardi; Jessica Hossa; Achille Pich; Luca Mologni; Carlo Gambacorti-Passerini; Laurence Brugières; Birgit Geoerger; Suzanne D Turner; Claudia Voena; Taek-Chin Cheong; Roberto Chiarle
Journal:  Blood       Date:  2022-02-03       Impact factor: 22.113

4.  Lack of TNFalpha expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis.

Authors:  Qian Zhang; Hong Y Wang; Gauri Bhutani; Xiaobin Liu; Michele Paessler; John W Tobias; Donald Baldwin; Kunchithapadam Swaminathan; Michael C Milone; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

5.  Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells.

Authors:  Koichi Nakase; Jihua Cheng; Quan Zhu; Wayne A Marasco
Journal:  J Leukoc Biol       Date:  2008-11-12       Impact factor: 4.962

Review 6.  Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.

Authors:  Melanie R Hassler; Aleksandra Klisaroska; Karoline Kollmann; Irene Steiner; Martin Bilban; Ana-Iris Schiefer; Veronika Sexl; Gerda Egger
Journal:  Biochimie       Date:  2012-06-09       Impact factor: 4.079

Review 7.  Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.

Authors:  Coralie Hoareau-Aveilla; Fabienne Meggetto
Journal:  Cancers (Basel)       Date:  2017-08-03       Impact factor: 6.639

8.  Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling.

Authors:  Melanie R Hassler; Walter Pulverer; Ranjani Lakshminarasimhan; Elisa Redl; Julia Hacker; Gavin D Garland; Olaf Merkel; Ana-Iris Schiefer; Ingrid Simonitsch-Klupp; Lukas Kenner; Daniel J Weisenberger; Andreas Weinhaeusel; Suzanne D Turner; Gerda Egger
Journal:  Cell Rep       Date:  2016-10-04       Impact factor: 9.423

Review 9.  Emerging epigenetic-modulating therapies in lymphoma.

Authors:  David Sermer; Laura Pasqualucci; Hans-Guido Wendel; Ari Melnick; Anas Younes
Journal:  Nat Rev Clin Oncol       Date:  2019-08       Impact factor: 66.675

Review 10.  Physiological and pathological implications of 5-hydroxymethylcytosine in diseases.

Authors:  Jing Liang; Fan Yang; Liang Zhao; Chongwei Bi; Benzhi Cai
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.